Australia-based Artrya Limited says its AI-enabled Salix Coronary Plaque module offers near real-time, point-of-care CCTA assessment and management of coronary artery disease. 

Greg Piefer, PhD, chief executive and founder of Shine, a Wisconsin-based radiopharmaceutical company that is building the world’s largest medical isotope production facility in Janesville, Wisconsin, explains progress on the company's fusion reactor that will become the first sustained U.S. commercial supplier of molybdenum-99 in decades.

Cardiology is number one in FDA Breakthrough Device designations at 218, the highest number out of all other clinical categories. This includes 16 new devices cleared in the past year.

“It is your responsibility to be the patient’s advocate,” one expert explained. “We, as the nurses and technologists, have to speak up when we see something that isn’t right.”

Greg Piefer, PhD, chief executive and founder of SHINE, a Wisconsin-based radiopharmaceutical company that is building the world’s largest medical isotope production facility in Janesville, Wisconsin, explains progress on the company's fusion reactor that will become the first U.S. commercial supplier of molybdenum-99 in decades.

New Hampshire-based Conformal Medical plans on using the funds to enroll more patients into an ongoing clinical trial. 

Heartflow has officially gone public after selling more than 19 million shares of common stock during an upsized IPO. The California medtech company, known for its AI-powered CCTA evaluations, is now being traded on Nasdaq under the symbol HTFL.

Pericarditis, inflammation of the pericardium, accounts for approximately 5% of all emergency department evaluations for chest pain. These new recommendations are designed to help guide clinicians through the ins and outs of patient care.